KCNH3 Inhibitors

Chemical inhibitors of the KCNH3 protein act by obstructing the ion flow through the protein's channels, which are essential for the physiological functions that involve the regulation of potassium ion conductance. Astemizole, for instance, blocks the hERG potassium channels, which are structurally related to the channels formed by KCNH3. By preventing potassium efflux, Astemizole inhibits the activity of KCNH3, disrupting its role in the repolarization phase of the cardiac action potential. Similarly, E-4031 is a specific blocker of hERG channels, thereby directly inhibiting KCNH3 by impeding the potassium current. Terfenadine, Dofetilide, and Ibutilide all share this mechanism of action, as they are known to inhibit hERG channels and in turn, inhibit KCNH3 by blocking the ion flow within these channels.

Clofilium Tosylate, although its direct interaction with KCNH3 has not been explicitly detailed, is known to block potassium channels, and thus it can be inferred to inhibit the function of KCNH3. Sotalol, a beta-blocker that also has the capacity to block hERG channels, inhibits KCNH3 by impeding the potassium current mediated by these channels. Disopyramide, Quinidine, Bepridil, Amiodarone, and Nifekalant, all exhibit inhibitory effects on hERG channels and therefore can inhibit KCNH3 in a similar fashion. By blocking these channels, they prevent the proper flow of potassium ions, which is critical for the electrical activity mediated by KCNH3. Such inhibition disrupts the physiological function of KCNH3, which plays a crucial role in the electrical signaling in the cells where it is expressed.